ArticleCarbohydrate research2017
The trehalose-specific transporter LpqY-SugABC is required for antimicrobial and anti-biofilm activity of trehalose analogues in Mycobacterium smegmatis.
Article in Carbohydrate research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 43 citations in OpenAlex.
- A Trehalose-Based Phenotypic Screen Identifies Candidate Inhibitors ofAntibiotics (Basel, Switzerland) · 2026Article
- Perspective Approaches to "Trojan Horse" Strategy Development for Combating Bacterial Pathogens.Pharmaceuticals (Basel, Switzerland) · 2026Review
- A Key Metabolic Protein in Active Mycobacterium tuberculosis: Insights into Carbon, Nitrogen, and Sulfur Metabolism.Advances in experimental medicine and biology · 2026Review
- Synthesis and evaluation of Trehalose-Pks13 inhibitor conjugates targeting mycobacteria.Carbohydrate research · 2025Article
- Effects of Trehalose on Halitosis: A Randomized Cross-Over Clinical Trial.Healthcare (Basel, Switzerland) · 2025Article
- Mycobacterial Biofilm: Mechanisms, Clinical Problems, and Treatments.International journal of molecular sciences · 2024Review
- Intracellular Protective Functions and Therapeutical Potential of Trehalose.Molecules (Basel, Switzerland) · 2024Review
- TargetingACS infectious diseases · 2024Article
- Chemical remodeling of the mycomembrane with chain-truncated lipids sensitizes mycobacteria to rifampicin.Chemical communications (Cambridge, England) · 2023Article
- Molecular recognition of trehalose and trehalose analogues byProceedings of the National Academy of Sciences of the United States of America · 2023Article
- Article
- Transcriptomic and Proteomic Analysis ofMicroorganisms · 2023Article
- TargetingViruses · 2023Review
- Chemical Reporters for Bacterial Glycans: Development and Applications.Chemical reviews · 2022Review
- PPE51 mediates uptake of trehalose across the mycomembrane of Mycobacterium tuberculosis.Scientific reports · 2022Article
- Dismantling the bacterial glycocalyx: Chemical tools to probe, perturb, and image bacterial glycans.Bioorganic & medicinal chemistry · 2021Review
- The ATP-Binding Cassette (ABC) Transport Systems inBiology · 2020Review
- The role of chemoenzymatic synthesis in advancing trehalose analogues as tools for combatting bacterial pathogens.Chemical communications (Cambridge, England) · 2020Article
- Structural basis of trehalose recycling by the ABC transporter LpqY-SugABC.Science advances · 2020Article
- Microbial and metabolic impacts of trehalose and trehalose analogues.Gut microbes · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Mycobacteria, including the bacterial pathogen that causes human tuberculosis, possess distinctive pathways for synthesizing and utilizing the non-mammalian disaccharide trehalose. Trehalose metabolism is essential for mycobacterial viability and has been linked to in vitro biofilm formation, which may bear relevance to in vivo drug tolerance. Previous research has shown that some trehalose analogues bearing modifications at the 6-position inhibit growth of various mycobacterial species. In this work, 2-, 5-, and 6-position-modified trehalose analogues were synthesized using our previously reported one-step chemoenzymatic method and shown to inhibit growth and biofilm formation in the two-to three-digit micromolar range in Mycobacterium smegmatis. The trehalose-specific ABC transporter LpqY-SugABC was essential for antimicrobial and anti-biofilm activity, suggesting that inhibition by monosubstituted trehalose analogues requires cellular uptake and does not proceed via direct action on extracellular targets such as antigen 85 acyltransferases or trehalose dimycolate hydrolase. Although the potency of the described compounds in in vitro growth and biofilm assays is moderate, this study reports the first trehalose-based mycobacterial biofilm inhibitors and reinforces the concept of exploiting unique sugar uptake pathways to deliver inhibitors and other chemical cargo to mycobacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.